Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors - CA223-001

Updated:   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1/Phase 2


  • Gender(s)

  • 18+

    Age Range

  • Recruiting

Treatment Options

Study Arms
Experimental: Part 1
Drug: Nivolumab Drug: Lirilumab
Experimental: Part 2 and 3: Cohort Expansion
Drug: Nivolumab Drug: Lirilumab
Experimental: Part 4: Cohort Expansion
Drug: Nivolumab Drug: Lirilumab
Experimental: Part 5 and 6
Drug: Ipilimumab Drug: Nivolumab Drug: Lirilumab

Key Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - During dose escalation, subjects with advanced solid tumors (except for primary CNS metastases) that have progressed following at least one standard regimen - During cohort expansion, subjects with various solid tumors that have received at least one and no more than 5 prior treatment regimens - Subjects must have measurable disease - Subject must consent to provide previously collected tumor tissue - Women and men ≥18 years of age with performance status of 0 or 1 - At least 4 weeks since any previous treatment for cancer Exclusion Criteria: - Active or chronic autoimmune diseases - Uncontrolled or significant cardiovascular disease - Chronic hepatitis (except for subjects with hepatocellular carcinoma) - Active infection - Active Central nervous system (CNS) metastases - Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome((HIV/AIDS) - Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except for subjects with hepatocellular carcinoma) Other protocol defined inclusion/exclusion criteria could apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us